Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | HSPA9 | P38646 | 1/20 | 0.42 |
| ▸ | OPRL1 | P41146 | 5/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14401667 | 0.89 | ALDH1A1 (0.44) | ALDH1A1MEN1KMT2AOPRL1GAA | |
| SCHEMBL14876380 | 0.88 | ALDH1A1 (0.44) | ALDH1A1MEN1KMT2AOPRL1GAA | |
| SCHEMBL12659939 | 0.88 | PPARG (0.48) | ALDH1A1 | |
| SCHEMBL13233697 | 0.88 | ALDH1A1 (0.43) | ALDH1A1MEN1KMT2AOPRL1GAA | |
| SCHEMBL14876547 | 0.82 | ANPEP (0.44) | ALDH1A1KMT2AOPRL1 | |
| SCHEMBL16315850 | 0.82 | TP53 (0.54) | ALDH1A1MEN1KMT2AGAA | |
| SCHEMBL30642153 | 0.81 | ALDH1A1 (0.61) | ALDH1A1MEN1KMT2AGAAL3MBTL1 | |
| SCHEMBL5007572 | 0.81 | ALDH1A1 (0.46) | ALDH1A1MEN1KMT2AOPRL1GAA | |
| SCHEMBL30642149 | 0.81 | ALDH1A1 (0.46) | ALDH1A1MEN1KMT2AOPRL1GAA | |
| SCHEMBL9205712 | 0.80 | CYP1A2 (0.46) | ALDH1A1MEN1KMT2AHSPA9L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1919920-B1 | PENTACYCLIC KINASE INHIBITORS | GENENTECH INC (US) | 2011-05-18 | — | — | EP | disclosed |
| US-7749994-B2 | Pentacyclic kinase inhibitors | GENENTECH, INC. (US) | 2010-07-06 | — | — | US | disclosed |
| US-20080318989-A1 | Pyrimidine Kinase Inhibitors | GENENTECH, INC. | 2008-12-25 | — | — | US | disclosed |
| CN-101287737-A | Pentacyclic kinase inhibitors | GENENTECH INC HOFFMANN LA ROCH (US) | 2008-10-15 | — | — | CN | disclosed |
| EP-1968950-A1 | PYRIMIDINE KINASE INHIBITORS | Genentech, Inc. (US) | 2008-09-17 | — | — | EP | disclosed |
| EP-1919920-A2 | PENTACYCLIC KINASE INHIBITORS | Genentech, Inc. (US) | 2008-05-14 | — | — | EP | disclosed |
| WO-2007120339-A1 | PYRIMIDINE KINASE INHIBITORS | GENENTECH, INC. (US) | 2007-10-25 | — | — | WO | disclosed |
| WO-2007022102-A2 | PENTACYCLIC KINASE INHIBITORS | GENENTECH, INC. (US) | 2007-02-22 | — | — | WO | disclosed |
| US-20070037791-A1 | serine/threonine kinase inhibitors, useful for therapy and/or prophylaxis of cancers in mammals | HOFFMAN-LAROUCHE, INC. | 2007-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080318989-A1 | Pyrimidine Kinase Inhibitors | DCK, DTYMK, TK1 | ALDH1A1 2990/4885MEN1 2188/4885KMT2A 1017/4885 |
| US-20070037791-A1 | serine/threonine kinase inhibitors, useful for therapy and/or prophylaxis of cancers in mammals | RAF1, CHEK1, BRAF | ALDH1A1 2759/4885MEN1 1193/4885KMT2A 981/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.